Skip to content
Markets News
Stocks1 min read

Recursion Shares Fall as Investors Await Financial Results

Makkler Newsroom
September 28, 2026

The stock lagged major indexes in the latest session, while Zacks estimates point to higher quarterly revenue and a smaller per-share loss.

Recursion Pharmaceuticals closed at $3.70 in the latest trading session, down 1.2% from the previous day. The decline was steeper than the S&P 500’s 0.77% loss, the Dow’s 0.67% drop and the Nasdaq’s 0.92% fall.

The biotechnology company’s shares gained 11.98% over the previous month. That outpaced the Medical sector, which fell 3.65%, and the S&P 500, which rose 0.96%.

Ahead of Recursion’s upcoming financial results, Zacks consensus estimates call for earnings per share of -$0.24 and revenue of $8.42 million. The projected earnings figure is up 33.33% from the prior-year quarter, while estimated revenue growth is 62.57%.

For the full year, Zacks estimates earnings of -$0.94 per share and revenue of $40.32 million. Those figures represent changes of 34.72% higher for earnings and 46.01% lower for revenue compared with the preceding year.

The consensus estimate for quarterly earnings per share has fallen 2.82% over the past month, according to Zacks.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.